ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2526

Bruton′s Tyrosine Kinase and Calreticulin: A Novel Interaction with Implications for Inflammatory and Autoimmune Disease

Jennifer C. Byrne1, Joan Ní Gabhann1, Kevin Stacey1, Barbara M. Coffey1, Eoghan M. McCarthy2, Warren Thomas3, Eamonn Molloy4, Grainne M. Kearns5 and Caroline Jefferies1, 1Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, 2Rheumatology, Beaumont Hospital, Dublin, Ireland, 3Molecular Medicine, Royal College of Surgeons in Ireland, Dublin 9, Ireland, 4Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 5Rheumatology Department, Beaumont Hospital, Dublin, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: macrophages, phagocytosis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Bruton’s Tyrosine Kinase (Btk) regulates innate immune responses downstream of multiple Toll-like receptors (TLRs), including TLR7. Given the role of TLR7 in driving type I interferon and inflammatory cytokine production in the autoimmune condition systemic lupus erythrematosus (SLE), pharmacological inhibition of the tyrosine kinase Btk has been proposed as a potential therapeutic. Given this interest it is essential that the role of Btk downstream of TLR7 activation be thoroughly explored.

Methods: Primary WT and Btk deficient murine macrophage were used to carry out a 2D proteomic study to identify differences downstream of TLR7 stimulation. Immunoprecipitation studies were carried out in macrophages and the human monocytic cell line THP-1. Confocal analysis was used to investigate localisation of proteins as well as uptake of apoptotic cells by primary macrophages.

Results: Our data describes a novel role for Btk as a regulator of the molecular chaperone calreticulin (CRT). Studies in primary macrophages demonstrate that CRT undergoes TLR7-induced tyrosine phosphorylation in a Btk-dependent manner. In addition Btk can directly interact with and phosphorylate CRT. Given the key role CRT in apoptotic cell uptake, we observe that in the absence of Btk, CRT fails to localise to the cell membrane or interact with the transmembrane receptor CD91, also known to be required for apoptotic cell uptake. Also, Btk-deficient macrophages show an impaired uptake of human apoptotic neutrophils in a phagocytosis assay as well as reduced staining for CRT within the phagocytic cup. In a preliminary study, pharmacological inhibition of Btk in monocytes derived from healthy controls demonstrated a reduction in apoptotic cell uptake following Btk inhibition, an effect that was exacerbated in monocytes derived from SLE patients.  

Conclusion: Overall our data has revealed a novel regulatory role for the tyrosine kinase Btk with regard to CRT. Loss of Btk results in an alteration in the cellular trafficking of CRT downstream of TLR7 stimulation in myeloid cells as well as a reduction in their ability clear apoptotic cells. Given the interest in the use of pharmacological inhibitors of Btk for the treatment of SLE, our data indicates that further investigation into the effect of Btk inhibition with regard to myeloid cell function is warranted.  

This work was funded by Science Foundation Ireland under grant no. 08/IN.1/B2091


Disclosure:

J. C. Byrne,
None;

J. Ní Gabhann,
None;

K. Stacey,
None;

B. M. Coffey,
None;

E. M. McCarthy,
None;

W. Thomas,
None;

E. Molloy,
None;

G. M. Kearns,
None;

C. Jefferies,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bruton%e2%80%b2s-tyrosine-kinase-and-calreticulin-a-novel-interaction-with-implications-for-inflammatory-and-autoimmune-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology